BioNTech SE (22UA) — Cash Flow Quality Index
Latest as of December 2024:
-1.79x
BioNTech SE (22UA) has a Cash Flow Quality Index of -1.79x as of December 2024. Operating cash flow of €-463.30 Million is below net income of €259.50 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore how well can BioNTech SE service its debt to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
-1.79x
Operating CF / Net Income
Operating Cash Flow
€-463.30 Million
EUR
Net Income
€259.50 Million
EUR
Data as of
Dec 2024
Most recent filing
BioNTech SE Cash Flow Quality Index (2020–2023)
Historical Cash Flow Quality Index for BioNTech SE across 4 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see BioNTech SE (22UA) cash flow conversion.
Annual Cash Flow Quality Index for BioNTech SE (2020–2023)
Year-by-year earnings quality comparison for BioNTech SE.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2023 | 5.77x | €5.37 Billion | €930.30 Million | ▲ +301.2% |
| 2022 | 1.44x | €13.58 Billion | €9.43 Billion | ▲ +1564.9% |
| 2021 | 0.09x | €889.70 Million | €10.29 Billion | ▲ +109.7% |
| 2020 | -0.89x | €-13.50 Million | €15.20 Million | — |
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.